title: Suppression of myoclonus in SCA2 by piracetam.
abstract: We report on a 30-year-old patient with advanced cerebellar degeneration due to SCA2. He presented with severe myoclonus, which was resistant to conventional therapy and dramatically improved after administration of 12-18 gm/die piracetam. Piracetam may be considered in the treatment of refractory myoclonus in spinocerebellar degenerations.
authors.affiliation: Department of Neurological Sciences, Federico II University, Naples, Italy.
authors.forename: Anna
authors.initials: A
authors.lastname: De Rosa
authors.forename: Pasquale
authors.initials: P
authors.lastname: Striano
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Barbieri
authors.forename: Arturo
authors.initials: A
authors.lastname: de Falco
authors.forename: Carlo
authors.initials: C
authors.lastname: Rinaldi
authors.forename: Tecla
authors.initials: T
authors.lastname: Tucci
authors.forename: Salvatore
authors.initials: S
authors.lastname: Striano
authors.forename: Alessandro
authors.initials: A
authors.lastname: Filla
authors.forename: Giuseppe
authors.initials: G
authors.lastname: De Michele
mesh_terms: D000328:Adult; D001259:Ataxia / Q000188:drug therapy* / Q000235:genetics; D000067528:Ataxins; D004305:Dose-Response Relationship, Drug; D020234:Gait Ataxia / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D009207:Myoclonus / Q000188:drug therapy* / Q000235:genetics; D009419:Nerve Tissue Proteins / Q000235:genetics*; D009460:Neurologic Examination / Q000187:drug effects; D010889:Piracetam / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D020754:Spinocerebellar Ataxias / Q000188:drug therapy* / Q000235:genetics; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis; D016896:Treatment Outcome; D018911:Trinucleotide Repeats / Q000235:genetics
chemical_list: D000067528:Ataxins; D009419:Nerve Tissue Proteins; D010889:Piracetam